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ABSTRACT
Background    DNA double-strand breaks (DSBs) are 
the most cytotoxic form of DNA damage and are in-
duced by ionizing radiation and specific chemotherapeu-
tic agents, such as topoisomerase inhibitors. Cancer cells 
acquire resistance to such therapies by repairing DNA 
DSBs. A major pathway for the repair of DNA DSBs is 
non-homologous end-joining (NHEJ), which requires 
DNA-dependent protein kinase (DNA-PK) activity. In 
this study, we investigated the effect of NU7441, a syn-
thetic small-molecule compound, as a specific inhibitor 
of DNA-PK on the chemosensitization of non-small cell 
lung carcinoma (NSCLC) A549 cells.
Methods    The combined effects of chemotherapeutic 
agents and NU7441 were evaluated by isobologram 
analysis using Cell Counting Kit-8. DNA DSBs were 
assessed by immunofluorescence assay. Apoptosis was 
examined by flow cytometry using an Annexin V apop-
tosis kit. Activation of DNA-PK was assayed by western 
blotting.
Results    The combination of NU7441 and topoisom-
erase inhibitors such as amrubicin and irinotecan had 
a synergistic effect on cell proliferation in A549 cells. 
NU7441 increased 53BP1 foci and apoptosis induced 
by topoisomerase inhibitors and decreased phos-
pho-DNA-dependent protein kinase, catalytic subunit 
(pDNA-PKcs) (S2056) protein expression caused by 
topoisomerase inhibitors. Interestingly, mitotic inhibitors 
such as pacritaxel did not cause the pDNA-PKcs (S2056) 
protein expression and the combination of NU7441 and 
pacritaxel had an only additive effect.
Conclusion    NU7441 inhibited the growth of NSCLC 
cells and enhanced the chemosensitization to topoisom-
erase inhibitors by blocking DNA repair. A combination 
of NU7441 and topoisomerase inhibitor may be a prom-
ising treatment for NSCLC.
Key words    DNA-dependent protein kinase; non-ho-
mologous end-joining; non-small cell lung carcinoma; 
NU7441; topoisomerase inhibitor
Non-small cell lung carcinoma (NSCLC) is one of the 
most commonly diagnosed cancers and the leading 
cause of cancer-related death worldwide. Over half of 
patients with NSCLC have been advanced or metastatic 
lesions at the time of diagnosis.1 Systemic chemotherapy 
is the standard treatment for patients with advanced NS-
CLC. In many countries, including Japan, cytotoxic che-
motherapeutic agents are used as the first-line treatment 
for advanced NSCLC patients. However, these cytotoxic 
chemotherapies have reached a therapeutic plateau and 
have limited survival benefits for advanced NSCLC pa-
tients. In recent years, treatment with targeted agents has 
markedly improved progression-free and overall survival 
in patients with advanced NSCLC harboring EGFR mu-
tation or ALK rearrangement.2, 3 However, only 20–30% 
of NSCLC patients harbor targets available for molecu-
lar targeting agents and most acquire resistance against 
molecular target agents within 1 year. Therefore, new 
agents and new combination chemotherapy regimens are 
required to improve the outcomes of all advanced NS-
CLC patients.
 DNA-dependent protein kinase, catalytic subunit 
(DNA-PKcs) is an essential component in the non-ho-
mologous end-joining (NHEJ) pathway of DNA dou-
ble-strand break (DSB) repair.4 In response to DNA 
DSBs, DNA-PKcs is rapidly recruited to damage sites 
by the Ku70/Ku80 heterodimer and phosphorylated at 
Thr2609 and Ser2056 clusters by ATM and itself, re-
spectively.5, 6 The recruitment and phosphorylation of 
DNA-PKcs contributes to the processing and direct liga-
tion of broken DNA ends. Several studies demonstrated 
increased protein levels of DNA-PKcs in NSCLC,7–9 and 
the elevation of DNA-PKcs has been correlated with 
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radioresistance in some advanced stage cancers.9 There-
fore, targeting of DNA-PKcs is an attractive approach 
for enhancing radio-sensitivity in NSCLC. Given its im-
portant role in the NHEJ repair pathway, different anti-
DNA-PKcs strategies have been explored to enhance the 
sensitivity to radiation or DNA damage-based agents. In 
a series of small-molecule ATP-competitive inhibitors 
of DNA-PKcs, NU7441 was found to be the most potent 
and specific inhibitor of DNA-PKcs at a low concentra-
tion relative to other members of the PI3KK family (ATM 
and ATR).10 Several studies have shown that NU7441 
can enhance the sensitivity to radiation in NSCLC.11 
However, little is known about the potency of NU7441 
in enhancing the sensitivity of cytotoxic chemotherapeu-
tic agents.
 Among cytotoxic anti-cancer drugs, topoisomer-
ase inhibitors target DNA topoisomerases, which are 
essential nuclear enzymes that catalyze the breakage 
and rejoining of DNA. There are two classes of DNA 
topoisomerases, type I and type II, which alter the topol-
ogy of single- and double-stranded DNA, respectively, 
and are involved in genetic reactions including DNA 
replication, transcription, and DNA repair.12 DNA to-
poisomerase inhibitors, such as irinotecan (CPT-11; topo 
I inhibitor) and amrubicin (AMR, topo II inhibitor), are 
important in lung cancer chemotherapy.13, 14
 In the present study, we evaluated the effect of 
combining topoisomerase inhibitors, which cause DNA 
damage, with DNA-PKcs inhibitors, which inhibit DNA-
DSB repair by blocking the NHEJ pathway, on NSCLC.
MATERIALS AND METHODS
Chemicals and reagents
AMR (Dainippon Sumitomo Pharma, Tokyo, Japan), 
CPT-11 (Daiichi Sankyo Pharma, Tokyo, Japan), and pa-
clitaxel (PTX) (Bristol-Myers-Squibb, New York, NY) 
were dissolved in distilled water and stored at –20 °C. 
NU7441 (AdooQ Bioscience, Irvine, CA) was dissolved 
in dimethyl sulfoxide and stored at –20 °C.
Cells
The lung adenocarcinoma A549 cell line was purchased 
from the American Type Culture Collection (ATCC, 
Manassas, VA). A549 cells were maintained in RPMI-
1640 medium supplemented with 10% fetal bovine se-
rum and antibiotics. These cells were grown in a humid-
ified atmosphere of 5% CO2 and 95% air at 37 °C.
Cell Counting Kit-8 (CCK-8) assay
A CCK-8 assay was performed to evaluate cell prolifer-
ation inhibition. Cells (1000 per well) were cultured in 
96-well flat-bottom multi-plates (Nalge Nunc, Penfield, 
NY) for 48 h. Next, the indicated drugs were added to 
the culture media. After 72 h of drug treatment, 10% 
CCK-8 solution (Dojindo, Kumamoto, Japan) was added 
to each well and incubation was continued for an addi-
tional 3 h. The absorbance of each well was measured at 
a wavelength of 450 nm using a Sunrise scanning multi-
well spectrometer (Tecan, Männedorf, Switzerland). 
Each experiment was performed in triplicate for each 
drug concentration.
Assessment of combination effect 
To qualitatively assess the combination effect of the indi-
cated agents, isobologram analysis was conducted as de-
scribed previously.15 The percentage of cell proliferation 
was calculated as: [(mean absorbance of drug-treated 
wells – mean absorbance of cell-free wells)/(mean ab-
sorbance of vehicle cells – mean absorbance of cellfree 
wells)] × 100. We used the concentration resulting in 
50% inhibition of cell growth (IC50) to evaluate dose-re-
sponse interactions.
Apoptosis assay
Apoptosis of A549 cells was detected by the Annexin V 
Apoptosis Detection Kit APC (eBioscience, San Diego, 
CA). A549 cells were treated with or without NU7441 
and with anticancer agents for 24 and 48 h. The cells 
were harvested by trypsinization, collected in centri-
fuge tubes, and washed with ice-cold phosphate-buff-
ered saline. Next, the cells were suspended in 500 μL 
of binding buffer and incubated with Annexin V-APC 
and propidium iodide or 4,6-diamidino-2-phenylindole 
(DAPI). The apoptotic population was assayed by flow 
cytometry (LSRFortessa X-20; BD Biosciences, Frank-
lin Lakes, NJ) and analyzed using FlowJo software 
(Treestar, San Carlos, CA).
Immunofluorescence staining
DNA-DSBs were assessed by quantifying the rates of 
dissolution of p53 binding protein 1 (53BP1) foci as de-
scribed. Immunofluorescence staining was performed 
in cells cultured in glass chamber slides (Lab-Tek II 
Chamber Slide w/Cover RS Glass Slide Sterile; Nalge 
Nunc). A549 cells were treated with or without NU7441, 
and then treated with each anticancer agent for 1 h. At 
the indicated times, cells were fixed with 4% PFA, per-
meabilized with 0.5% Triton X-100, and immunostained 
with 53BP1 primary antibody (diluted 1:1000; Cell 
Signaling Technologies, Beverly, MA) and Alexa Fluor 
488 goat anti-rabbit secondary antibody (diluted 1:2000; 
Life Technologies, Carlsbad, CA). The nuclei of cells 
were stained using blue fluorescent DAPI in Vectashield 
mounting medium (Vector Laboratories, Burlingame, 
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CA). Images were obtained with a fluorescence micro-
scope (BZ-9000; Keyence, Osaka, Japan). The 53BP1 
foci per nucleus were visually counted in the acquired 
images.
Western blotting
Intracellular proteins from cells treated with AMR, CPT-
11, or PTX and with or without NU7441 at the indicated 
concentrations and time points were prepared using 
NE-PER Nuclear and Cytoplasmic Extraction Reagents 
(Thermo Scientific, Waltham, MA). Proteins were mea-
sured using the Bio-Rad Protein assay reagent (Bio-Rad 
Laboratories, Hercules, CA), and protein lysates contain-
ing 45 μg of total intracellular protein were subjected to 
discontinuous SDS-polyacrylamide gel electrophoresis. 
Proteins were electrotransferred to a polyvinylidene 
fluoride membrane (GE Healthcare, Little Chalfont, 
UK) overnight at 4 °C at 45 V. Non-specific binding was 
blocked by incubation with 5% bovine serum albumin 
or non-fat milk in Tris-buffered saline containing 0.1% 
Tween-20 for 2 h at room temperature. The following 
primary antibodies were used: anti-DNA-PKcs (diluted 
1:1000; Thermo Scientific), anti-phospho-DNA-PKcs 
(Serine2056) (diluted 1:5000; AbCam, Cambridge, MA), 
and anti-Lamin B (diluted 1:1000; AbCam) overnight 
and washed twice with Tris-buffered saline containing 
0.1% Tween-20. After washing, proteins were detected 
by incubation with horseradish peroxidase-labeled sec-
ondary antibodies (GE Healthcare). Each protein was 
detected using an enhanced chemiluminescence detec-
tion system (ECL prime) (GE Healthcare) and detected 
using ImageQuant LAS400 (GE Healthcare).
Data analysis
The experimental data was analyzed by using Graphpad 
Prism (Graphpad Software, San Diego, CA). The results 
were expressed as the mean ± standard deviation. Two 
independent samples were analyzed by the t-test.
RESULTS
Combination effects of NU7441 and chemothera-
peutic agents
First, we assessed the IC50 concentrations of chemother-
apeutic agents and NU7441 on A549 cells in the CCK-
8 assay at 72 h. The IC50 values of AMR, CPT-11, PTX, 
and NU7441 on A549 cells were 3.1 μM, 27 μM, 7.5 
nM, and 0.8 μM, respectively, and these results were 
similar to those of previous reports.16–18 We evaluated the 
combination effects of NU7441 and chemotherapeutic 
agents in A549 cells by isobologram analysis. Represen-
tative results of isobologram analysis are shown in Fig. 
1. The combination of NU7441 with AMR and CPT-
11 synergistically inhibited cell growth, whereas only 
additive effects were observed for the combination of 
NU7441 and PTX. We conducted the analyses at least 
three times and similar trends were obtained.
DNA DSB induced by chemotherapeutic agents 
and combination effect of NU7441
To evaluate DNA damage caused by chemotherapeutic 
agents and the additional effect of NU7441, we subject-
ed A549 cells exposed to chemotherapeutic agents with 
or without NU7441 to immunofluorescence staining 
for 53BP1 (green), a DNA damage response factor.19 As 
shown in Fig. 2, we observed 53BP1 foci in the nuclei of 
A549 cells exposed to AMR and CPT-11. Furthermore, 
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Figure 1. 	
Fig. 1. Combination effects of NU7441 and chemotherapeutic agents in A549 cells. 
A549 cells were treated with a combination of NU7441 and AMR, CPT-11, or PTX for 72 h. The combination effects were evaluated by 
isobologram analysis. The envelopes of additivity are defined by three isoeffect lines constructed from the dose-response curves of the 
single agents. The concentration resulting in 50% cell growth inhibition (IC50) of NU7441, AMR, CPT-11, or PTX alone is expressed as 
one on the ordinate and the abscissa. The plotted data points show the relative values of the concentrations resulting in the IC50. AMR, 
amrubicin; CPT-11, irinotecan; IC50, 50% inhibition of cell growth; PTX, paclitaxel.
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Fig. 2. DNA DSBs in A549 cells exposed to chemotherapeutic agents in the presence and absence of DNA-PK inhibitor (NU7441). 
A549 cells were treated with the IC50 dose of AMR (3 μM), CPT-11 (25 μM), or PTX (7.5 nM) for 1 h with or without NU7441 (10 μM, 
1 h prior to chemotherapeutic agent exposure) and samples were immunostained with anti-53BP1 antibodies (green) and DAPI (blue) at 
1 h (A) and 24 h (B) after chemotherapeutic agent exposure. Representative images for each condition are shown. Percentages of cells 
with > 10 53BP1 foci treated as in A (C) and B (D). Date are expressed as the mean ± SE (n = 3). *P < 0.05. 53BP1, p53 binding protein 
1; AMR, amrubicin; CPT-11, irinotecan; DAPI, 4,6-diamidino-2-phenylindole; DNA-PK, DNA-dependent protein kinase; DSB, dou-
ble-strand break; IC50, 50% inhibition of cell growth; ns, not significant; NU, NU7441; PTX, pacritaxel.
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the number of cells with 53BP1 foci increased under 
combination treatment with NU74441. In contrast, the 
number of 53BP1 foci in the nuclei of A549 cells ex-
posed to PTX was similar to the control condition and 
did not increase following the addition of NU7441. To 
quantify DNA DSB, we counted and graphed the num-
ber of cells with > 10 53BP1 foci. Immediately after 
drug exposure, the rate of cells with > 10 53BP1 foci 
treated with a combination of AMR and NU7441 was 
higher than that of cells treated with only AMR (P < 0.05, 
Fig. 2B). At 24 h after drug exposure, the rate of cells 
with > 10 53BP1 foci treated with a combination of CPT-
11 and NU7441 was higher than that treated with only 
CPT-11 (P < 0.05, Fig. 2D). In contrast, the rate of cells 
with > 10 53BP1 foci did not increase following combi-
nation treatment with PTX and NU7441. Unfortunately, 
the cells at 24 h after exposure of AMR were difficult to 
evaluate because of large changes in cell morphology.
Apoptotic effects of NU7441 and chemotherapeu-
tic agents
To investigate the combination effect of NU7441 and 
chemotherapeutic agents on cell apoptosis, we assayed 
the cells treated with or without NU7441 and with 
AMR, CPT-11, or PTX for 24 or 48 h using an Annexin 
V apoptosis kit. At 24 h after drug exposure (Fig. 3A), 
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Fig. 3. Apoptotic effect of combinations of NU7441 and chemotherapeutic agents.
A549 cells were treated with IC50 dose of AMR (3 μM), CPT-11 (25 μM), or PTX (7.5 nM) for 24 and 48 h with or without NU7441 (2.5 
μM, 1 h prior to chemotherapeutic agent exposure). Samples were assayed with Annexin V. Bar graphs representing the percentage of 
apoptosis cells at 24 h (A) and 48 h (B). Date are expressed as the mean ± SE (n = 3). *P < 0.05. AMR, amrubicin; CPT-11, irinotecan; 
IC50, 50% inhibition of cell growth; ns, not significant; NU, NU7441; PTX, pacritaxel.
AMR significantly increased apoptosis following addi-
tion of NU7441. At 48 h after drug exposure (Fig. 3B), 
CPT clearly increased apoptosis when NU7441 was also 
added. In contrast, PTX induced apoptosis, but there 
was no combination effect with NU7441. Unfortunately, 
apoptosis at 48 h after exposure of AMR was difficult to 
evaluate because of the high rate of cell death.
Activation of DNA-PKcs induced by chemothera-
peutic agents and suppression effect by NU7441
To assess the activation of DNA-PKcs induced by che-
motherapeutic agents in NSCLC cells at different con-
centrations and times, we detected pDNA-PKcs (S2056) 
protein expression in the nuclei of A549 cells exposed 
to PTX, CPT-11, and AMR by western blotting. The 
nuclear proteins were extracted using NE-PER nuclear 
and cytoplasmic extraction reagents. After 1-h exposure, 
AMR clearly activated DNA-PKcs, while PTX and 
CPT-11 only slightly activated DNA-PKcs (Fig. 4A). 
After long-term incubation (12 and 24 h), following 1-h 
drug exposure, CPT-11 clearly activated DNA-PKcs over 
time, while PTX did not show this activation effect (Fig. 
4B). These results suggest that the timing and intensity 
of phosphorylation of DNA-PKcs depends on the che-
motherapeutic agent used. In addition, the activation of 
DNA-PKcs induced by chemotherapeutic agents was 
suppressed by NU7441.
Figure 4. 
	  A	   	  B	  	  
Fig. 4. Activation of DNA-PKcs induced by chemotherapeutic agents and effect of DNA-PK inhibitor (NU7441). 
(A) A549 cells were pre-treated with or without a DNA-PKcs inhibitor (NU7441, 10 μM) and treated with 1/10 IC50 dose or IC50 dose of 
PTX (0.75 nM, 7.5 nM), CPT-11 (2.5 μM, 25 μM), or AMR (0.3 μM, 3 μM) for 1 h. Activation of DNA-PKcs was assayed by western 
blotting with antibodies as indicated. (B) A549 cells were pre-treated with or without NU7441 (10 μM) and treated with IC50 dose of PTX 
(7.5 nM) or CPT-11 (25 μM). Activation of DNA-PKcs was assayed at 1, 12, or 24 h after 1-h treatment with each agent by western blot-
ting using the indicated antibodies. AMR, amrubicin; CPT-11, irinotecan; DNA-PKcs, DNA-dependent protein kinase catalytic subunit; 
IC50, 50% inhibition of cell growth; pDNA-PKcs, phospho-DNA-dependent protein kinase catalytic subunit; PTX, paclitaxel.
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DISCUSSION
DNA-PKcs is an essential component of the NHEJ path-
way and activation of DNA-PKcs is required for DNA 
DSB repair.20 Inhibiting phosphorylation of DNA-PKcs 
blocks DNA damage repair and leads to cell apoptosis. 
NU7441, a potent and specific DNA-PKcs inhibitor, 
has been predicted to enhance the therapeutic effect of 
inducing DNA DSB. Previously, several studies showed 
that NU7441 has potential for enhancing the radio-sen-
sitivity in different tumors, including NSCLC,11 colon 
cancer,21 breast cancer,22 and prostate cancer,23 and che-
mo-sensitivity of etoposide (topoisomerase II inhibitor) 
in colon cancer.21 The goal of this study was to deter-
mine the best combination drug for use with NU7441 to 
enhance the anti-proliferative effect on NSCLCs.
 In this study, a DNA-PKcs inhibitor showed promise 
in combination pharmacological medicine with specific 
chemotherapeutic agents against lung cancer. The DNA-
PKcs inhibitor had a synergistic anti-proliferative effect 
on the A549 lung cancer cell line when applied with 
topoisomerase inhibitors. Interestingly, the inhibitor 
only had an additive effect with the mitotic inhibitor. 
Topoisomerases have been examined for use in the 
treatment of certain diseases. Among them, eukaryotic 
topoisomerases I and II are targets of anti-cancer drugs 
that act to inhibit these enzymes by blocking the reaction 
that reseals breaks in the DNA.24 Topoisomerase I inhib-
itors, including CPT-11, induce single-strand breaks in 
DNA by blocking the dissociation of topoisomerase and 
DNA, leading to replication-mediated DNA damage. 
Topoisomerase II inhibitors, including AMR, can act by 
either stabilizing topoisomerase II-DNA complexes that 
are easily cleaved or interfering with the catalytic activ-
ity of the enzyme, both resulting in DSBs. In contrast, 
mitotic inhibitors, including PTX, bind to tubulin and 
inhibit its polymerization into microtubules, resulting 
in tumors and leading to apoptosis without involvement 
with DSBs.25, 26
 Phosphorylation of DNA-PKcs occurs at the S2056 
site,5 which provides a marker for assessing the effect 
of drugs on DNA-PKcs activity. In this study, we found 
that topoisomerase inhibitor induced DNA-PKcs phos-
phorylation of A549. Topoisomerase II inhibitor AMR 
immediately phosphorylated DNA-PKcs, whereas to-
poisomerase I inhibitor CPT-11 only minimally induced 
DNA-PKcs phosphorylation immediately after exposure 
to drugs and gradually phosphorylated DNA-PKcs over 
time. This delay in DNA-PKcs phosphorylation may be 
related to the time required to shift from single-strand 
breaks to DSBs. NU7441 clearly inhibited DNA-PKcs 
phosphorylation caused by both AMR and CPT-11. 
 In this study, we assessed the degree of DNA DSBs 
using 53BP1 foci as a marker of DNA DSB.19 AMR and 
CPT-11 caused DNA DSBs, whereas PTX caused few 
DNA DSBs. The combined use of NU7441 induced a 
greater number of DNA DSBs. In addition, NU7441 
in combination with topoisomerase inhibitors induced 
apoptosis by more than the use of topoisomerase inhibi-
tors alone. 
 This is the first study to demonstrate that the DNA-
PKcs inhibitor Nu7441 has a synergistic effect with 
topoisomerase inhibitors, but not with a mitotic inhibi-
tor, on NSCLC cells. Recently, several clinical studies 
revealed that DNA-PKcs expression is significantly ele-
vated in advanced disease and that an elevation in acti-
vated DNA-PKcs predicts the response to treatment and 
survival.27, 28 Further, DNA-PKcs inhibitors are currently 
in phase I trials for advanced solid tumors and hemato-
logic malignancies (NCT01280487, NCT01421524, and 
NCT01682473) and the efficacy of DNA-PKcs inhibitors 
has been demonstrated in clinical trials.29 Based on our 
results, further studies, including preclinical studies and 
clinical trials, are necessary to clarify the efficacy of this 
combination therapy with NU7441 and topoisomerase 
inhibitors in NSCLC.
 In conclusion, NU7441 blocks DNA damage repair 
induced by topoisomerase inhibitors in NCSLC cells and 
subsequently leads to their apoptosis. Therefore, our re-
sults suggest that combination therapy of topoisomerase 
inhibitors and NU7441 is a potential therapeutic option 
for NCSLC.
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